Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy

June 11, 2026 10:48 AM EDT News Briefing Sen­so­ri­on ax­es hear­ing loss pro­gram; No­var­tis' bio­mark­er da­ta in mus­cu­lar dy­s­tro­phy ENDPOINTS Plus, news about Imaavy. 👂 Sen­so­ri­on se­lects one hear­ing loss pro­gram, ax­es an­oth­er: The biotech is end­ing the de­vel­op­ment of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER